Biogen, AGTC enter agreement to develop gene therapies in ophthalmology

Biogen and AGTC have entered into a collaboration and licensing agreement to develop gene-based therapies for multiple ophthalmic diseases, according to a press release from Biogen. Lead development programs include a clinical candidate for X-linked retinoschisis and a preclinical candidate for the treatment of X-linked retinitis pigmentosa, the release said.